The core activity of DAMIAN PHARMA AG is the development and marketing of pharmaceutical products, in particular the development of therapies for rare diseases such as Primary Aldosteronism (PA).
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of targeted therapies for Primary Aldosteronism and other aldosterone-dependent diseases, focusing on diagnosis, localization, and treatment.
Dexfadrostat phosphate (DP13)
Aldosterone synthase inhibitor in clinical development for the medical treatment of Primary Aldosteronism, following Phase I and Phase II studies.
DP14 diagnostic tracer
PET tracer in the research phase for imaging and localization of aldosterone-producing benign tumours without specialized surgery.
Comparisons
DAMIAN PHARMA AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank DAMIAN PHARMA AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once DAMIAN PHARMA AG has claimed this profile, we'll publish editorial articles and case studies here together.